



ABN: 15 129 742 409

dorsaVi Ltd Secondary Trading Notice

Notice given under Section 708A(5)(e) of the Corporations Act

Melbourne, Australia – 30 January 2017: This notice is given by dorsaVi Ltd (ASX: DVL (**dorsaVi** or **Company**)) under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) (as modified by ASIC Class Order 14/827 (**Class Order**)).

Background - Placement

dorsaVi announced on 13 December 2016 that it had received commitments from sophisticated and institutional investors to subscribe for 15,217,393 new fully paid ordinary shares in the Company (**New Shares**) at A\$0.46 per New Share to raise A\$7.0 million in two tranches (**Placement**).

dorsaVi announced on 19 December 2016 that it had allotted 10,869,565 New Shares to complete Tranche 1 of the Placement. A\$5.0 million of the A\$7.0 million was raised under Tranche 1.

dorsaVi announced on 25 January 2017 that following the approval granted at an extraordinary general meeting of dorsaVi's shareholders held on 20 January 2017, it had allotted 4,347,828 New Shares (**Tranche 2 New Shares**) at A\$0.46 per New Share under the second of the two tranches (**Tranche 2**) to raise the remaining A\$2.0 million to complete the Placement. In accordance with the shareholder approval granted, these Tranche 2 New Shares were issued to major shareholder Starfish Technology Fund II (Trust A and Trust B). The Tranche 2 New Shares rank equally with the Company's existing ordinary shares.

Background – Share Purchase Plan

dorsaVi announced on 25 January 2017 that following the successful completion of its share purchase plan (**SPP**) announced on 13 December 2016, 2,173,850 new fully paid ordinary shares had been issued (**SPP Shares**). The SPP was capped at A\$1 million and the purchase price for each SPP Share was A\$0.46, the same as the issue price under the Placement. The SPP Shares rank equally with the Company's existing ordinary shares.

Statements by dorsaVi

dorsaVi relies on section 708A(5)(e) of the Corporations Act (as modified by the Class Order) and gives notice that it has issued the Tranche 2 New Shares and SPP Shares without disclosure to investors under Part 6D.2 of the Corporations Act.

As at the date of this notice, dorsaVi:

- 1 has complied with the provisions of Chapter 2M of the Corporations Act as they apply to dorsaVi, and section 674 of the Corporations Act; and
- 2 confirms that, there is no information:
 - (a) that has been excluded from a continuous disclosure notice given to ASX in accordance with the ASX Listing Rules; and
 - (b) that investors and their professional advisers would reasonably require for the purpose of making an informed assessment of:

For personal use only

- (i) the assets and liabilities, financial position and performance, profits and losses and prospects of dorsaVi; and
- (ii) the rights and liabilities attaching to dorsaVi's securities,

to the extent to which it would be reasonable to investors and their professional advisers to expect to find such information in a disclosure document.

About dorsaVi

dorsaVi (ASX:DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in elite sports, occupational health and safety, and clinical applications. dorsaVi believes its wearable sensor technology enables – for the first time – many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours.

Our technology has applications across three sectors:

- **Clinical:** ViMove is transforming the management of patients by providing an objective assessment, monitoring outside the clinic and immediate biofeedback. ViMove is currently used by medical and physiotherapy practices in Australia and the United Kingdom and is now available in the United States following FDA 510K clearance.
- **Elite Sports:** ViPerform is allowing coaches and medical teams managing elite athletes and teams to screen athletes and provide objective evidence for decisions on return to play, measure biomechanics and provide immediate biofeedback out on the field, tailor and track training programs and optimise technique and peak performance. ViPerform is being used by AFL and NRL clubs and the Australian Institute of Sport (AIS) in Australia. In the UK, Barclays Premier League (EPL), U.S. based sports clubs including the National Basketball Association (NBA) and the National Football League (NFL), and various Olympic teams and athletes internationally.
- **OHS:** We combine innovation, measurement and quality to reduce workplace incidents, costs, meet compliance and improve brand reputation. ViSafe enables employers to assess the risk of injury for employees as well as test the effectiveness of proposed changes to workplace design, equipment or methods based on objective evidence. ViSafe has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor), Crown and BHP Billiton. Australian Workplace Compliance delivers risk mitigation through compliance to OHS, Quality Management Systems, Company Policy and Process.

Further information is available at www.dorsavi.com.

For personal use only